GlassScriptPhysician profile
Joel B Capucao
NPI 1972639334
$6,490.66
in general payments reported to CMS, 2019-2025
22 companies · $693 in 2025
The $693 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $220 · 2021: $559 · 2022: $1,918 · 2023: $2,083 · 2024: $381 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.52 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,212.04 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $945.38 | 2022-2025 | Caplyta |
| Alkermes, INC. | $527.84 | 2021-2023 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $491.04 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $460.27 | 2019-2022 | |
| Corium, LLC | $390.37 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $346.81 | 2019-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $302.50 | 2021-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $245.54 | 2019-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $228.39 | 2022 | |
| Allergan, INC. | $225.48 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $216.65 | 2019-2023 | Austedo, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $172.23 | 2021-2024 | Jornay Pm |
| Lundbeck LLC | $132.59 | 2019-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $110.77 | 2025 | Spravato |
| Bausch Health US, LLC | $86.55 | 2020-2023 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $85.22 | 2020-2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $67.40 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $58.87 | 2022-2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $36.12 | 2019 | |
| Tris Pharma INC | $23.60 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Capucao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.